Professional
Added to YB: 2026-05-22
Pitch date: 2026-05-11
KDV-B.ST [bullish]
KDventures AB
Author Info
We perform researched powered investment banking with a belief that Scandinavia will be a hotspot for the major future innovations within tech and lifescience. Visit their website.
Company Info
KDventures AB is a venture capital firm specializing in investments in growth capital, seed stage, and early stage companies.
Market Cap
SEK 199.4M
Pitch Price
N/A
Price Target
1.00
Dividend
N/A
EV/EBITDA
-5.24
P/E
-0.46
EV/Sales
60.13
Sector
Pharmaceuticals
Category
value
KDventures: Out of the Shadow, Into the Light
KDV-B.ST: Listed VC in Nordic biotech at ~85% NAV discount. Crown jewel Umecrine (60% portfolio) targeting brain fog/fatigue in PBC w/ phase IIa readout H2 2026—positive data positions for major exit. Dilafor (20% NAV) validated via Exeltis deal, phase III underway, est. 2028 readout. Modus phase IIa in Q4 2026 could trigger revaluation/licensing. Rights issue (SEK115M) funds ops through 2027. Base case SEK1.0 (~400% upside), bull SEK1.7 on Umecrine success, bear SEK0.4 on failure. Risk: 80%+ NAV in 2 binary assets.
Read full article (37 min)